Global Isocitrate Dehydrogenase Inhibitors Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Isocitrate Dehydrogenase Inhibitors market size will reach US$ million by 2031.
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
LPI (LP Information)' newest research report, the “Isocitrate Dehydrogenase Inhibitors Industry Forecast” looks at past sales and reviews total world Isocitrate Dehydrogenase Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Isocitrate Dehydrogenase Inhibitors sales for 2025 through 2031. With Isocitrate Dehydrogenase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Isocitrate Dehydrogenase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Isocitrate Dehydrogenase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Isocitrate Dehydrogenase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Isocitrate Dehydrogenase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Isocitrate Dehydrogenase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Isocitrate Dehydrogenase Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Isocitrate Dehydrogenase Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segmentation by Application:
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Please note: The report will take approximately 2 business days to prepare and deliver.
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
LPI (LP Information)' newest research report, the “Isocitrate Dehydrogenase Inhibitors Industry Forecast” looks at past sales and reviews total world Isocitrate Dehydrogenase Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Isocitrate Dehydrogenase Inhibitors sales for 2025 through 2031. With Isocitrate Dehydrogenase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Isocitrate Dehydrogenase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Isocitrate Dehydrogenase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Isocitrate Dehydrogenase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Isocitrate Dehydrogenase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Isocitrate Dehydrogenase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Isocitrate Dehydrogenase Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Isocitrate Dehydrogenase Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Segmentation by Application:
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
119 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Isocitrate Dehydrogenase Inhibitors Market Size by Player
- 4 Isocitrate Dehydrogenase Inhibitors by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Isocitrate Dehydrogenase Inhibitors Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
